Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × iratumumab × Sarcoma × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡